Biosimilars: Friend or foe to healthcare?
Our article in Pharma Market Europe and our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.
Biologics, whose active substance is derived from a living organism, have enabled healthcare to make significant therapeutic advances across a whole raft of therapy areas since their introduction in the 1970s. However, these medicines come at a price, reflecting the complexities involved in developing and manufacturing products derived from living cells. Annual treatment costs in the US can range from US$25,000 to US$200,000. Biosimilars medicines, the follow-on “generics” to biologics which have come off-patent, present a significant opportunity to introduce cutting-edge therapies to the treatment landscape for many diseases, while also addressing the cost-effectiveness demands now being made on global healthcare systems.
Annual donation made to Forever Angels baby home
Access Partnership and Research Partnership have made a seasonal donation to its chosen charity, Forever Angels this week of US$2,000.
Access Partnership and Research Partnership have made a seasonal donation to their chosen charity, Forever Angels this week of US$2,000.
Thanks to the incredible efforts of our staff, we also raised a further $1,102 for the charity through various fundraising activities, bringing our total donation this winter to $3,102. Employees have been partaking in various fundraising initiatives throughout 2013 to raise money for this worthy cause.
New location for our UK headquarters
On 21st January 2013 Access Partnership relocated to new UK Headquarters.
On 21st January 2013 Access Partnership relocated to new UK Headquarters. We are committed to a strategy of growth, with investment into key areas, and our new premises allow us to expand our operations and deliver our high quality market access and consultancy services from a larger, newly renovated office site in London. Further appointments will be announced shortly.